Agios to Participate in December Investor Conference

On November 30, 2022 Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, reported that the company is scheduled to present at the Bank of America 2022 Virtual Biotech SMID Cap Conference on Wednesday, December 7, 2022, at 11:25 a.m. ET (Press release, Agios Pharmaceuticals, NOV 30, 2022, View Source [SID1234624580]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

Vivesto announces that Christer Nordstedt will remain as acting CEO during a transition period

On November 30, 2022 Vivesto AB, an oncology-focused specialty pharma company, reported that the company’s acting CEO Christer Nordstedt will remain in his position part-time until Vivesto’s new permanent CEO Erik Kinnman takes up his position (Press release, Vivesto, NOV 30, 2022, View Source [SID1234624576]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 21, 2022, Vivesto announced that Erik Kinnman was appointed as the new CEO of Vivesto, effective no later than May 20, 2023. Vivesto has today agreed with Christer Nordstedt that he will remain in his current position as acting CEO of Vivesto on a part-time basis until Erik Kinnman takes office.

"We are very pleased that Christer can remain in his role as acting CEO of Vivesto. During the short time he has been with us, Christer has demonstrated his broad competence and long experience from the industry, and we look forward to a seamless transition until Erik Kinnman takes office. It is also gratifying that Christer will continue to contribute to the company’s development as a senior advisor in R&D," said Peter Zonabend, Chairman of the Board of Vivesto.

As of December 1, 2022, Christer Nordstedt will also hold the position as CEO of Oblique Therapeutics AB.

ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

On November 30, 2022 ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, reported that it has completed enrolment in its Phase 2 clinical trial named OpcemISA (Press release, ISA Pharmaceuticals, NOV 30, 2022, View Source [SID1234624575]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The OpcemISA trial has enrolled 194 patients and is a large randomized, double blind, placebo-controlled Phase 2 clinical trial. The trial will evaluate the efficacy and safety of the addition of ISA101b to checkpoint inhibitor therapy in patients with metastatic/advanced 1st and 2nd line HPV16 positive OPC. Primary endpoints will demonstrate overall response rate (ORR) and safety. Secondary endpoints include duration of response (DOR) and overall survival (OS). This trial is part of an extensive clinical development program of ISA101b in collaboration with US biotechnology company Regeneron.

"This large proof of concept trial of ISA101b has the potential to demonstrate for the first time that the combination of an HPV16-directed therapeutic vaccine with checkpoint inhibitor immunotherapy improves the short-term outcome and longer-term survival of difficult to treat head and neck cancer patients. The completion of enrolment is a major milestone for ISA Pharmaceuticals as it continues development of its SLP technology platform. We look forward to presenting top line interim data from this trial in the third quarter of next year." said Dr. Leon Hooftman, Chief Medical Officer of ISA Pharmaceuticals.

Head-and-neck cancer can be a severe and life-threatening disease. HPV16 is a major cause of head-and-neck cancer. Recurrent and metastatic HPV16 positive OPC is a form of head-and-neck cancer with a high unmet medical need. In September 2021 ISA101b was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent and metastatic HPV16 positive oropharyngeal cancer (OPC).

HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit

On November 30, 2022 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported that the company will participate virtually in investor meetings and panel discussions at The JMP Securities Hematology and Oncology Summit, December 6 – 7, 2022 (Press release, Hookipa Pharma, NOV 30, 2022, View Source [SID1234624574]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences

On November 29, 2022 SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, reported that it has exercised its first of five exclusive, target-specific options with LegoChem Biosciences for antibody-drug conjugate (ADC) SOT106, which is currently being evaluated in preclinical studies across a multitude of solid tumor indications (Press release, SOTIO, NOV 29, 2022, View Source [SID1234626212]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In November of 2021, SOTIO and LCB entered into a multi-target exclusive collaboration and license agreement under which SOTIO obtained the rights to deploy LCB’s ADC technology for up to five ADC programs. SOTIO is responsible for the research, development, manufacturing and worldwide commercialization of the ADC products.

"We are pleased with the progress we have made this year on our innovative antibody-drug conjugate pipeline. We advanced our lead program targeting CLDN18.2, SOT102 into the Phase 1 dose escalation portion of the CLAUDIO-01 trial and have now exercised this option for SOT106. ADCs remain one of the most actively pursued drug classes in oncology and we are encouraged that SOT106, an ADC with the potential to treat some of the most challenging solid tumor indications, continues to show promise in preclinical studies," said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. "The rapid and successful development of this collaboration with LegoChem Biosciences reiterates our commitment to providing patients with efficacious and safe cancer therapeutic options."

"We are very excited that a successful outcome has been achieved in such a short time since the partnership launched a year ago." said Dr. Yong-Zu Kim, the CEO & President of LCB. "This result has come from a combination of SOTIO’s deep antibody discovery expertise and LegoChem’s industry-leading and differentiated ADC platform technology. We look forward to further achieving progress in our efficient and close partnership as this effort continues into generating new drug candidates."

The exercise of the first option triggers an undisclosed milestone payment by SOTIO to LCB.

About SOT106
SOT106 is a novel ADC based on SOTIO Biotech’s proprietary antibodies and LCB’s industry-leading ConjuAllTM ADC platform technology with potential best-in class efficacy, safety and tolerability currently in preclinical development against multiple solid tumor indications.